For research use only
Back to shop
NAD+

Purity

≥ 98% (HPLC)

Longevity
Cellular & Longevity
Neurological
Metabolic Research

NAD+

Coenzyme

$90.00· 500mg · Lyophilized Vial

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme central to cellular energy metabolism and DNA repair. It is investigated for anti-aging, energy, and cognitive-support applications in research.

1
In stock & ready to ship Discreet packaging

Studied Mechanism

Serves as an essential redox cofactor and substrate for sirtuins and PARPs — enzymes tied to DNA repair, mitochondrial function, and cellular-aging pathways studied in longevity research.

Research References

For Research Use Only — Not for Human Consumption

For laboratory research use only. Not for human consumption. Not a drug, food, or cosmetic. Not intended to diagnose, treat, cure, or prevent any disease. Products are sold exclusively to qualified researchers and institutions. By purchasing, you confirm you are using these materials for lawful, in-vitro research purposes and assume all responsibility for safe handling.

Related compounds

LUCENT
Labs
MOTS-C
10 mgResearch Use Only

Mitochondrial-Derived Compound

Purity ≥ 98% (HPLC)
$65.00

Longevity

MOTS-C

Studied Mechanism

Studied for activating AMPK signaling and translocating to the nucleus under metabolic stress to regulate genes governing glucose handling and metabolic homeostasis in study models.

Full page
LUCENT
Labs
GHK-Cu
100 mgResearch Use Only

Copper Complex

Purity ≥ 98% (HPLC)
$65.00

Cosmetic

GHK-Cu

Studied Mechanism

Modulates expression of a broad set of genes toward a 'younger' profile, stimulating collagen, elastin, and glycosaminoglycan synthesis and supporting antioxidant and remodeling pathways in study models.

Full page
LUCENT
Labs
IPAMORELIN/ CJC1295
10 mgResearch Use Only

GHRH Analog + GH Secretagogue

Purity ≥ 98% (HPLC)
$100.00

Growth Hormone

Ipamorelin / CJC1295

Studied Mechanism

Ipamorelin selectively agonizes the GHS-R1a receptor for pulsatile GH release; CJC-1295 acts on pituitary GHRH receptors to raise the GH/IGF-1 baseline. The combination targets complementary GH-release pathways.

Full page